鼻内催产素改善老年肌少性肥胖患者瘦肌肉量并降低LDL胆固醇:一项初步随机对照试验
结果显示催产素耐受性良好,与安慰剂相比显著增加全身瘦肌肉量2.25 kg(P < .01),并显著降低血浆LDL胆固醇19.3 mg/dL(P = .023),但BMI、食欲、血糖、HDL、甘油三酯及抑郁症状无显著变化。
要点
- 鼻内催产素(24 IU每日4次,8周)在老年肌少性肥胖患者中耐受性良好,无显著不良事件。
- 与安慰剂相比,催产素显著增加全身瘦肌肉量2.25 kg(P < .01),并显著降低LDL胆固醇19.3 mg/dL(P = .023)。
- BMI、食欲评分、血糖、HDL、甘油三酯及抑郁症状未见显著变化。
核心结论
- 这项概念验证研究提示催产素可能对老年肌少性肥胖的治疗有用,并可能提供额外的心血管获益。
研究设计与样本
- 双盲、安慰剂对照随机对照试验,鼻内催产素(24 IU,每日4次)治疗8周。
主要发现
- 基线时BMI为36.8 ± 3.6 kg/m2,脂肪量46.09 ± 6.99 kg,瘦体重50.98 ± 11.77 kg,空腹血糖92.0 ± 8.9 mg/dL,HbA1c 5.7% ± 0.4%,LDL 111.3 ± 41.5 mg/dL,HDL 47.85 ± 10.96 mg/dL,甘油三酯140.55 ± 83.50 mg/dL。
- 催产素给药耐受良好,无显著不良事件。
- 与安慰剂相比,催产素使全身瘦体重显著增加2.25 kg(P < .01),脂肪量有下降趋势。
- 与安慰剂相比,催产素使血浆LDL胆固醇显著降低19.3 mg/dL(P = .023)。
- BMI、食欲评分、血糖、血浆HDL、甘油三酯或抑郁症状无显著变化。
临床怎么用
- 对于老年肌少性肥胖患者,鼻内催产素可能作为改善瘦体重和降低LDL胆固醇的潜在干预手段,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Obesity is associated with sarcopenia in older adults, and weight loss can lead to further muscle mass loss. Oxytocin decreases with age, and animal studies suggest that oxytocin administration has trophic effects on skeletal muscle cells and reduces adiposity. We conducted a clinical trial to examine the safety and preliminary efficacy of intranasal oxytocin for older adults with sarcopenic obesity. DESIGN: A double-blind, placebo-controlled randomized controlled trial of intranasal oxytocin (24 IU 4 times per day) for 8 weeks. SETTING AND PARTICIPANTS: Twenty-one older (67.5 ± 5.4 years), obese (30-43 kg/m2), sedentary (<2 strenuous exercise per week) adults with slow gait speed (<1 m/s, proxy measure of sarcopenia) were recruited. MEASURES: Generalized estimating equations were used to evaluate the effect of oxytocin on safety/tolerability of oxytocin administration and whole body muscle and fat mass. RESULTS: At baseline, body mass index (BMI) was 36.8 ± 3.6 kg/m2, fat mass 46.09 ± 6.99 kg, lean mass 50.98 ± 11.77 kg, fasting plasma glucose (FPG) 92.0 ± 8.9 mg/dL, hemoglobin A1c (HbA1c) 5.7% ± 0.4%, low density lipoprotein (LDL) 111.3 ± 41.5 mg/dL, high-density lipoprotein (HDL) 47.85 ± 10.96 mg/dL, and triglycerides 140.55 ± 83.50 mg/dL. Oxytocin administration was well tolerated without any significant adverse events. Oxytocin led to a significant increase of 2.25 kg in whole body lean mass compared with placebo (P < .01) with a trend toward decreasing fat mass, and a significantly reduced plasma LDL cholesterol by -19.3 mg/dL (P = .023) compared against placebo. There were no significant changes in BMI, appetite scores, glycemia, plasma HDL, triglycerides, or depressive symptoms. CONCLUSIONS AND IMPLICATIONS: This proof-of-concept study indicates that oxytocin may be useful for the treatment of sarcopenic obesity in older adults. Oxytocin administration may also provide additional cardiovascular benefits.
引用
- Espinoza SE, Lee JL, Wang CP, et al. Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: A Pilot Randomized Controlled Trial. J Am Med Dir Assoc. 2021. PMID: 34029521. doi:10.1016/j.jamda.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。